Novo Nordisk signs licensing agreement for obesity drug with Hengrui Pharma
A licensing agreement expands access to an obesity drug candidate and alters future supply/commercialization rights.
Source →The trace
How it reaches your house.
Starting from GLP-1 drugs (Ozempic, Wegovy, Mounjaro), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
GLP-1 drugs (Ozempic, Wegovy, Mounjaro) →supply upHRS-1596 (GLP-1/GIP dual agonist)
Novo's exclusive rights to develop, manufacture and commercialise the phase I-ready oral GLP-1/GIP agonist should raise the odds of future availability for this obesity-drug candidate.
“HRS-1596 is a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing”
82% confidenceCited →GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type) →Stands to benefitNovo NordiskNVO
Novo is the company in the licensing deal, and on this edge it is the dominant/sole-qualified participant linked to the GLP-1 peptide API, so the expanded obesity pipeline can benefit it commercially, albeit indirectly for this specific input.
58% confidence
Where it lands
What you buy, and what you own.
Goods you buy
HRS-1596 (GLP-1/GIP dual agonist)
In the MyPRIA app, this is checked against your own holdings.